Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Other, SGLT2i Aug 02 | 2024Tirzepatide SUMMIT HFpEF Topline Results; Regeneron, Alnylam, Ionis, Teladoc, Amarin, and Biomea Q2 ’24 Earnings; Antag Increases Series A Funding for GIP Antagonism; Sanofi Expands Insulin Manufacturing in Germany; Boston Pharmaceuticals MASH UpdatesPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Aug 01 | 2024FENIX Analysis: GLP-1RA Promotional Materials Post-ADA 2024Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Jul 30 | 2024Pfizer and Merck Q2 ’24 Earnings Updates; Fractyl Receives FDA Breakthrough Designation for Revita; NewAmsterdam Announces Ph3 HeFH Data; Liraglutide Associated with Decreased Risk of Cognitive DeclinePurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucagon, Other Jul 29 | 2024Roche Ph2 Obesity Trial Observed; Altimmune Ph1 MASLD Data PublishedPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Jul 26 | 2024Dexcom Q2 ’24 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucagon, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jul 25 | 2024Wegovy SELECT Positive CHMP Opinion; AZ, Viking, Roche, and Sanofi Q2 ’24 Earnings UpdatesPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Jul 25 | 2024UK MHRA Approves SELECT; Skye Obesity Development Plans; New Lilly Obesity Ads ObservedPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Jul 24 | 2024BioAge Initiates Ph2 POC Oral Azelaprag+Tirzepatide Combination Trial in Obesity; TIXiMED Receives IND Approval from FDA for Oral Non-Immunosuppresive T1DM Drug; Novo Buys Land in Denmark for Potential Production PlantPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Jul 23 | 2024July CHMP Agenda; Hims & Hers Appoints Kåre Schultz to BOD; G&L Ph2b Obesity Results; Tirzepatide and Semaglutide Approved in China for ObesityPurchase Blast
$599
Posted in: Bolus Insulin, GLP-1RA, Glucose Monitoring, Other Jul 19 | 2024Abbott and Novartis Q2 ’24 EarningsPurchase Blast
$599
Posted in: GLP-1RA, Other Jul 18 | 2024Roche Positive Ph1 Oral GLP-1RA Obesity ResultsPurchase Blast
$599
Posted in: Dual/triple agonist, Other, SGLT2i Jul 17 | 2024Roche Ph1b Obesity Results; CordenPharma Invests $982M to Expand GLP-1RA Capacity in US and EU; Lexicon Receives PDUFA Date for Sotagliflozin in T1DM; Lexicon Publishes Additional Inpefa Cost-Effectiveness AnalysisPurchase Blast
$599
Posted in: GLP-1RA Jul 12 | 2024Ozempic Associated with Decreased Risk of Dementia Among Other OutcomesPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Other Jul 12 | 2024Pfizer Advances QD Danuglipron; Skye Establishes Clinical Advisory Board; Tonghua Dongbao Discontinues BioChaperone Combo Partnership with Adocia; FTC Prepares to Sue Three Largest PBMsPurchase Blast$599
Posted in: Basal Insulin Jul 10 | 2024Novo Nordisk’s QW Insulin Icodec Receives CRLPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery Jul 10 | 2024Roche CGM Receives CE Mark; Lilly Beats Novo in GLP-1RA Observational Study; Pfizer Leadership Change; FTC Releases Prescription Drug Middlemen Interim Staff ReportPurchase Blast
$599
Posted in: Dual/triple agonist, Other Jul 08 | 2024Mounjaro Olympics DTC; Xeris CEO Succession Plan; Lexicon Appoints New CEO and Director; Inventiva NATiV3 Lanifibranor UpdatesPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Jul 02 | 2024BI Announces Triple Agonist for Obesity Treatment; Merck Initiates Ph2a Trial of Efinopegdutide in MASLDPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other Jun 28 | 2024Novo to Bring Connected Care to Ozempic; New Novo Ph1 Oral Amycretin Trial; Dexcom Moves Manufacturing to Arizona; US House Advances Medicare Obesity Bill; Esperion Enters Purchase Agreement with OMERSPurchase Blast
$599
Posted in: GLP-1RA, Other Jun 26 | 2024Novo’s Ocedurenone CLARION-CKD Trial Fails; NeuroBo Doses First Patient in MAD Ph1 Obesity Trial; Another Generic Liraglutide FDA ApprovalPurchase Blast